Next-generation sequencing to impact all aspects of care for myelodysplastic syndrome


Incorporation of next-generation sequencing into standard of practice will be required for patients with myelodysplastic syndrome and will impact all facets of care, according to a presenter at Chemotherapy Foundation Symposium.

Cost may be a consideration and faster turnaround times are important, David A. Sallman, MD, assistant member of the department of malignant hematology at Moffitt Cancer Center, said during his presentation.

The impact of next-generation sequencing on diagnosis will continue to evolve and already has been evidenced by the incorporation of SF3B1 mutation presence to help diagnose myelodysplastic syndrome with ringed sideroblasts, he said.


Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.